Cancer Research The Future of Cancer Research: Science and Patient Impact  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 41, 1682-1689, May 1, 1981]
© 1981 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neuwald, P. D.
Right arrow Articles by Brooks, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neuwald, P. D.
Right arrow Articles by Brooks, M.

Altered Form of Placental Alkaline Phosphatase Produced by JAR Choriocarcinoma Cells in Culture1

Paul D. Neuwald2 and Mindy Brooks

Biological Markers Program, National Cancer Institute-Frederick Cancer Research Center, Frederick, Maryland 21701

The alkaline phosphatase activity expressed by JAR choriocarcinoma cells was compared to the placental isoenzyme of human alkaline phosphatase by several criteria. JAR cell alkaline phosphatase was similar to the placental isoenzyme with respect to heat and urea stability and sensitivity to most inhibitors, but it differed significantly from placental alkaline phosphatase in its sensitivity to L-phenylalanylglycylglycine. In contrast to the serum form of placental alkaline phosphatase, the JAR cell enzyme was highly hydrophobic as determined by octyl agarose chromatography and appeared to be larger than the placental isoenzyme based on gel filtration and polyacrylamide gel electrophoresis. The slowly migrating hydrophobic JAR cell activity could be converted into a fast-migrating hydrophilic form similar to the serum placental isoenzyme by treatment with trypsin-like proteases. Conversion to the hydrophilic form was accompanied by a decrease in subunit molecular weight from 68,000 to 66,000, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 33P-labeled enzyme. Peptide mapping of the 33P-labeled molecules by limited proteolysis in the presence of sodium dodecyl sulfate showed JAR cell alkaline phosphatase to be closely related to the placental isoenzyme with respect to primary structure. However, placental alkaline phosphatase appeared to be richer in sialic acid residues than was the JAR cell enzyme. We conclude that JAR cells produce a form of placental alkaline phosphatase that contains a hydrophobic region not associated with the free serum enzyme and that the tumor cell enzyme is modified or processed differently than is the enzyme found in the term placenta.

1 Research supported by the National Cancer Institute under Contract NO1-CO-75380 with Litton Bionetics, Inc.

2 To whom requests for reprints should be addressed.

Received 7/ 2/80. Accepted 1/29/81.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1981 by the American Association for Cancer Research.